NDA/PLA REVIEWS MAY NOT BE DELAYED DUE TO GENERAL DATA INTEGRITY ISSUES UNDER PhRMA FDA REFORM PLAN; OTC OFFICE WOULD RETURN TO REVIEW ALL SWITCHES
FDA's "applications integrity policy" would be overturned by a provision of the Pharmaceutical Research & Manufacturers of America FDA reform plan.